A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop ...

Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of ...

NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein ...

known as targeted protein degradation or PROTAC, which repurposes a cell's recycling system for therapy." More information: Shawn C. Massoni et al, MdfA is a novel ClpC adaptor protein that ...

ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in ...

Noah Berkowitz, CMO at Arvinas, said: “The ability of ARV-102 to cross the blood-brain barrier and degrade the LRRK2 protein offers ... of evidence for this lead PROTAC degrader candidate ...